NCT05884372

Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Xi'an Honghui Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Primary objective: To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density. Secondary objective: To compare the efficacy of denosumab with eldecalcitol or native vitamin D treatment in postmenopausal women with osteoporosis on bone turnover markers, serum PTH, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.

Conditions

• Osteoporosis in Postmenopausal Women

Interventions

Type	Name	Description
DRUG	Eldecalcitol	the same as arm descriptions.
DRUG	Native Vitamin D	the same as arm descriptions.
DRUG	Denosumab	the same as arm descriptions.
DRUG	Calcium	the same as arm descriptions.

Timeline

• Start date: 2023-08-24
• Primary completion: 2025-07-16
• Completion: 2025-07-16
• First posted: 2023-06-01
• Last updated: 2025-11-24

Locations

1 site across 1 country: China